Market Research Logo

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2016’, provides in depth analysis on Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Overview
Therapeutics Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Stage of Development
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Therapy Area
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Indication
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Products under Development by Companies
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma, Inc.
Eli Lilly and Company
G1 Therapeutics, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Onconova Therapeutics, Inc.
Pfizer Inc.
Presage Biosciences, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
Teijin Pharma Limited
Theryte Limited
Tiziana Life Sciences Plc
Vichem Chemie Research Ltd.
ViroStatics srl
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1748 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMD-37K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Projects
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Featured News & Press Releases
Jul 06, 2016: Study Tests New Breast Cancer Drug In African American Women
Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors
Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy
May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data
May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO
May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer
Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer
Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)
Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting
Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting
Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows
Mar 07, 2016: New therapeutic target in myeloma discovered
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Beta Pharma, Inc., H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by G1 Therapeutics, Inc., H2 2016
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Onconova Therapeutics, Inc., H2 2016
Pipeline by Pfizer Inc., H2 2016
Pipeline by Presage Biosciences, Inc., H2 2016
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016
Pipeline by Teijin Pharma Limited, H2 2016
Pipeline by Theryte Limited, H2 2016
Pipeline by Tiziana Life Sciences Plc, H2 2016
Pipeline by Vichem Chemie Research Ltd., H2 2016
Pipeline by ViroStatics srl, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report